Novo Integrated Sciences, INC

Novo Integrated Sciences extends the resignation date of its CEO and announces the resignation of a board member.

Novo Integrated Sciences, Inc. (NVOS) is set to be delisted from the Nasdaq Stock Market after failing to meet the minimum bid price requirement, with trading continuing on the OTC Market.

Novo Integrated Sciences announces another extension to the resignation date of CEO Robert Mattacchione to facilitate a smoother transition.

Novo Integrated Sciences, Inc. announces a further extension to the resignation date of CEO Robert Mattacchione to ensure a smooth transition.

Novo Integrated Sciences extends the resignation date of CEO Robert Mattacchione to no later than March 7, 2025, to ensure a smooth transition.

Robert Mattacchione's resignation as CEO of Novo Integrated Sciences has been extended to February 20, 2025, to facilitate a smoother transition.

Novo Integrated Sciences reported its Q3 2024 financial results, showing a net loss and ongoing efforts to manage debt and improve operations.

Novo Integrated Sciences, Inc. reports a 24% increase in revenue for the second quarter of 2024 compared to the same period last year, driven primarily by product sales.

Novo Integrated Sciences saw a revenue increase in the first quarter of 2024, but also experienced a larger net loss compared to the same period last year.

Novo Integrated Sciences outlines its capital structure, business model, and growth strategies in its annual 10-K filing, emphasizing its focus on decentralized healthcare and product development.

Christopher David Mehlin, COO of Novo Integrated Sciences, was granted a stock option to purchase 200,000 shares of the company's common stock.

Novo Integrated Sciences has withdrawn a proposal for potential share issuance due to its delisting from the Nasdaq Capital Market, while still proceeding with other key proposals at its upcoming annual meeting.

Novo Integrated Sciences' CEO, Robert Mattacchione, has resigned effective February 5, 2025, but will remain as Chairman of the Board and Chairman of a subsidiary.

Novo Integrated Sciences is holding a virtual annual meeting on November 22, 2024, seeking stockholder approval for director elections, a potential stock issuance, a reverse stock split, and auditor ratification.

Novo Integrated Sciences has filed a registration statement for the resale of up to 3.5 million shares of common stock by a selling securityholder following the conversion of a secured convertible promissory note.